Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib study of GLPG2451 + GLPG2222 with or without GLPG2737 in adults with cystic fibrosis
NL-OMON46421Phase 1Active, not recruiting
- Sponsor
- Galapagos NV
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GLPG2451, galicaftor and GLPG2737 in cystic fibrosis (CF), sponsored by Galapagos NV. Primary endpoints: Safety and tolerability, Pharmacokinetics of study drugs and active metabolites and 2 more. Started Jul 2018; status: active, not recruiting.
02
Drugs
GLPG2451galicaftorGLPG2737
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON46421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46421.